| Date | Title | Description |
| 27.10.2025 | Швейцарская Novartis покупает американскую биотехнологическую компанию Avidity за $12 млрд | Компания Novartis AG согласилась приобрести Avidity Biosciences Inc. за $12 млрд, что стало крупнейшей сделкой швейцарского производителя лекарств за последние более чем десять лет. Приобретение добавляет несколько потенциальных препаратов-... |
| 26.10.2025 | Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash | Swiss pharmaceutical giant Novartis has agreed to buy biotechnology company Avidity Biosciences for about $12 billion, the company said Sunday.
Novartis will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Fr... |
| 01.05.2025 | Швейцарская Novartis купит производителя лекарств от заболеваний почек Regulus за $1,7 млрд | Согласно условиям сделки, Novartis выплатит $7 за акцию наличными авансом, или около $800 млн, и еще $7 за акцию акционерам Regulus, если основной кандидат на лекарственный препарат, Фарабурсен, получит одобрение регулирующих органов, сообщ... |
| 10.08.2021 | Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates | |
| 03.08.2021 | Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call | |
| 21.05.2021 | Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program | |
| 06.05.2021 | Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call | |
| 03.05.2021 | Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |
| 15.04.2021 | Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |
| 10.02.2021 | Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |
| 27.01.2021 | Regulus Announces Addition to Board of Directors | |
| 08.12.2020 |
Regulus Therapeutics Finds $19.4M In Private Placement
| La Jolla-based biopharmaceuticals company Regulus Therapeutics announced this morning that it has raised $19.4M in a private placement. The publicly traded company, which trades on the Nasdaq as RGLS, said it sold 24,341,607 shares of the C... |
| 08.12.2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity | |
| 02.11.2020 | Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with Sanofi | |
| 13.10.2020 | Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from Sanofi | |
| 31.08.2020 | Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements | |
| 06.05.2019 | Esperion shares surge as FDA waves off panel review; Adaptimmune buoyed by a positive data snapshot | Derek Archila
→ Esperion got a 15% bump on its stock price $ESPR this morning after the biotech reported that the FDA had said it didn’t expect to call an advisory panel together to review the newly accepted NDAs for be... |
| 06.11.2018 | With its back against the wall, Regulus hands over its lead microRNA drug to Sanofi for a small down payment | Just a few weeks after a troubled Regulus Therapeutics $RGLS pulled off a reverse split of its stock, the biotech is handing off its lead drug — now in Phase II — to its partners at Sanofi. And they’re not getting much for it.
Re... |
| 09.07.2018 | Cash-strapped Regulus braces for drastic downsizing while hitting the brakes on lead programs | Still suffering from financial woes triggered by a streak of setbacks over the past two years, Regulus Therapeutics is now putting its two clinical programs on hold — and axing 60% of its remaining staff.
The news landed q... |
| 04.05.2017 | Stuck on FDA hold, Regulus CEO hits the exit as reorganization slashes staff at the beleaguered biotech | With their lead drug stuck on a full clinical hold and no hope of relief before the end of this year — a year after it had initially forecast the end of its spell in purgatory — Regulus Therapeutics $RGLS is bidding goodby... |
| 27.01.2017 | Regulus ordered to remain in limbo as FDA refuses to lift hold, demanding more data on lead drug | Regulus is still in the FDA’s doghouse. Regulators have stiff armed the biotech, refusing to lift a clinical hold on the hep C drug RG-101 and blowing far past the company’s promise to get everything wrapped and hopefully ba... |
| 07.12.2016 | Ariad’s brigatinib scores 15.6 month PFS rate; Neurimmune backs ALS spinout | David Ross Camidge, MD, PhD
Ariad Pharmaceuticals is reporting that its ALK inhibitor brigatinib scored a 55% objective response rate in among patients taking 180 mg. In this same arm the PFS rate was a median 15.6 months. “... |
| 28.10.2010 | Regulus Therapeutics Receives $10M Equity Investment from Sanofi-Aventis | Regulus Therapeutics Inc., a San Diego, CA-based biopharmaceutical company focused on the discovery and development of innovative new medicines targeting microRNAs, has received a $10m equity investment from sanofi-aventis.
The investment, ... |
| 28.10.2010 |
Regulus Therapeutics Gets $10M From Sanofi-Aventis
| La Jolla-based Regulus Therapeutics reports today that it has received $10M in an equity investment from drug maker Sanofi-Aventis. The firm said the investment came as part of its strategic alliance with Sanofi-Aventis, which was signed Ju... |
| 04.03.2009 |
Regulus Therapeutics Raises $20M
| Carlsbad-based Regulus Therapeutics, a biopharmaceuticals firm focused on microRNA-based therapeutics, announced this morning that it has raised $20M in a Series A funding round. The investment came from Alnylam Pharmaceuticals and Isis Pha... |
